Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates World First Multiple Mechanisms of Action against E. coli bacteria
June 01, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327 (R327) Mechanism of Action ‘unlike that of any antibiotic seen before’ with multiple mechanisms identified in independent study - to be presented at upcoming World Microbe...
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Progresses to Stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO
May 20, 2021 10:12 ET
|
Recce Pharmaceuticals
Summary: Further study completed at the Doherty Institute as part of SARS-CoV-2 Antiviral Screening Program calculates IC50 of RECCE® 327 (R327) to be 2,046 PPM and the CC50 for R327 to be 5108...
Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens
May 04, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studiesR327 remains effective against...
Recce Pharmaceuticals Announces Positive Data Against Streptococcus pneumoniae Sinusitis Infection in Animal Model
April 01, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: Positive sinusitis infection data indicated in animal study Study supports broad spectrum potential of Recce’s anti-infective compounds against Streptococcus pneumoniae (S. pneumoniae)...
Recce Pharmaceuticals Announces The Pew Charitable Trusts' Addition of Recce’s Lead Compound RECCE® 327 to List of Antibiotic Treatments in Clinical Development
March 15, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327 included in The Pew Charitable Trusts’ annual assessment of non-traditional antibiotic treatment in clinical developmentRECCE® 327 is the only synthetic polymer drug candidate...
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange
March 09, 2021 08:00 ET
|
Recce Pharmaceuticals
Shares now trading on major German Trading Exchanges Shares trade under code: R9QNo related capital raising - trade of existing securities with trade volume to increase on Australian Stock Exchange...
Recce Pharmaceuticals Applies for Dual Listing on FSE (Frankfurt Stock Exchange)
February 24, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: Broadens institutional and retail investor base across EU and enables access to additional capital markets No related capital raising - trade of existing securities with trade...
Recce Pharmaceuticals Announces Encouraging Results from Anti-viral Screening Program at The Doherty Institute Evaluating RECCE® 327 Against SARS-CoV-2
February 16, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327, a synthetic anti-infective 99.9% efficacious in confirmatory in-vitro screening assay against SARS-CoV-2 virusSARS-CoV-2 virus no longer detectable by virus titration at 4,000...
Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds
February 16, 2021 08:00 ET
|
Recce Pharmaceuticals
Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western AustraliaStudy led by world leading burn treatment specialistsStudy will assess safety and efficacy of...
Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study
December 23, 2020 08:00 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327 and RECCE® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection Intranasal administration of...